Metagenomi is editing its pipeline, choosing to seek a partner for a program Moderna dropped and axing its amyotrophic lateral sclerosis (ALS) activities in response to setbacks at a competitor. The ...
LEXINGTON, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it has decided to ...
NEWTON, Mass., November 13, 2025--(BUSINESS WIRE)--Inflammasome Therapeutics (https://www.inflam.com), a clinical-stage biotech company developing a new class of drugs, Kamuvudines, for ophthalmic and ...
NEW YORK, Feb. 27, 2025 /PRNewswire/ -- Woolsey Pharmaceuticals today announced the successful completion of an extension to its Series B Preferred financing round by existing investors. Woolsey ...
SALT LAKE CITY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage ...
LOS ANGELES (Sept. 30, 2014) – The ALS Program at Cedars-Sinai has become the first in Southern California to be named an ALS Association Certified Treatment Center of Excellence – a distinction that ...
Cytokinetics will stop further testing of its experimental amyotrophic lateral sclerosis drug after an early look at the data found it was unlikely to succeed. The result comes four years after the ...
NEW ORLEANS & BOSTON--(BUSINESS WIRE)--Team Gleason, a leading foundation for ALS patient support, is collaborating with Boston Children’s Hospital’s ALS Augmentative Communication Program, which ...
The Acton Fire Department is celebrating marking the end of the second year of its ALS program. The department officially transitioned from Basic Life Support to Advanced Life Support on Sept. 5, 2017 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results